Advancing the next generation of cancer treatment with circular RNAs in CAR-T cell therapy DOI Open Access

Sanxiong Huang,

Juling Xu,

Natalia Baran

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 181, P. 117753 - 117753

Published: Dec. 1, 2024

Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematological malignancies. However, its effectiveness against solid tumors remains constrained by challenges such as exhaustion, limited persistence, and off-target effects. These highlight critical gaps in current CAR-T cell therapeutic strategies, particularly for tumor applications. Circular RNAs (circRNAs) represent a transformative class non-coding RNAs, known their exceptional stability precise regulatory functions, positioning them promising candidates enhancing next-generation therapies. Notably, circRNAs can bridge gap between preclinical research clinical application offering innovative solutions to overcome technical hurdles improve outcomes. Despite potential, remain underexplored therapies tumors, presenting significant opportunity innovation. The mechanisms through which modulate specificity are not yet fully understood, challenges, achieving efficient targeted circRNA delivery, still need be addressed. This review highlights importance integrating into enhance specificity, minimize effects, durability. By emphasizing potential identifying key gaps, this provides roadmap advancing setting stage next generation personalized cancer treatments.

Language: Английский

Advances in Immunotherapy and Targeted Therapy for Gastric Cancer: A Comprehensive Review DOI

Hui Yuan,

Miao Bao, M. Chen

et al.

British Journal of Hospital Medicine, Journal Year: 2025, Volume and Issue: 86(3), P. 1 - 24

Published: March 26, 2025

Gastric cancer remains one of the most prevalent and lethal malignancies worldwide, characterized by poor survival rates, particularly in advanced stages. In recent years, a paradigm shift gastric treatment has been witnessed with introduction immunotherapy targeted therapies. This review provides detailed examination current immunotherapeutic strategies, including adoptive cell therapy (ACT), immune checkpoint inhibitors (ICIs), vaccines. Additionally, it explores advancements therapies, focusing on human epidermal growth factor receptor 2 (HER2) vascular endothelial (VEGFR) signaling pathways, as well emerging targets such claudin 18.2. Clinical trials investigating chimeric antigen T-cell (CAR-T) therapy, receptor-engineered (TCR-T) natural killer (NK) cell-based treatments have shown promise, when combined conventional chemotherapeutic regimens. However, challenges cytokine release syndrome, immune-related toxicities, scalability issues remain significant. The combination therapies represents promising approach to enhance outcomes. Future directions emphasize need overcome resistance mechanisms refine strategies improve efficacy while reducing adverse effects. aims elucidate landscape explore their potential shaping future clinical management for this devastating disease.

Language: Английский

Citations

0
Machine learning-based prognostic modelling of NK cells in PAAD for immunotherapy guidance DOI Creative Commons
Li Li,

Wu Zz,

Wanxing Duan

et al.

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: April 20, 2025

Language: Английский

Citations

0
Staying on target in gene and cell therapy DOI
Courtney Bricker-Anthony,

Dwight D. Koeberl,

Gerald S. Lipshutz

et al.

Molecular Therapy, Journal Year: 2024, Volume and Issue: 32(9), P. 2801 - 2802

Published: Aug. 23, 2024

Language: Английский

Citations

1
Advancing the next generation of cancer treatment with circular RNAs in CAR-T cell therapy DOI Open Access

Sanxiong Huang,

Juling Xu,

Natalia Baran

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 181, P. 117753 - 117753

Published: Dec. 1, 2024

Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematological malignancies. However, its effectiveness against solid tumors remains constrained by challenges such as exhaustion, limited persistence, and off-target effects. These highlight critical gaps in current CAR-T cell therapeutic strategies, particularly for tumor applications. Circular RNAs (circRNAs) represent a transformative class non-coding RNAs, known their exceptional stability precise regulatory functions, positioning them promising candidates enhancing next-generation therapies. Notably, circRNAs can bridge gap between preclinical research clinical application offering innovative solutions to overcome technical hurdles improve outcomes. Despite potential, remain underexplored therapies tumors, presenting significant opportunity innovation. The mechanisms through which modulate specificity are not yet fully understood, challenges, achieving efficient targeted circRNA delivery, still need be addressed. This review highlights importance integrating into enhance specificity, minimize effects, durability. By emphasizing potential identifying key gaps, this provides roadmap advancing setting stage next generation personalized cancer treatments.

Language: Английский

Citations

1